GT Biopharma, Inc.
GTBP
$2.89
$0.228.24%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 20.48% | 3.75% | -25.58% | -33.29% | -42.87% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.80% | -14.93% | -33.85% | -33.25% | -36.13% |
| Operating Income | -5.80% | 14.93% | 33.85% | 33.25% | 36.13% |
| Income Before Tax | -73.25% | -20.84% | 22.68% | 38.51% | 63.62% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -73.25% | -20.84% | 22.68% | 38.51% | 63.62% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -73.25% | -20.84% | 22.68% | 38.51% | 63.62% |
| EBIT | -5.80% | 14.93% | 33.85% | 33.25% | 36.13% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -24.93% | 13.54% | 42.65% | 52.54% | 71.46% |
| Normalized Basic EPS | -13.89% | 18.77% | 44.80% | 53.98% | 68.64% |
| EPS Diluted | -24.93% | 14.21% | 43.03% | 53.26% | 71.78% |
| Normalized Diluted EPS | -13.89% | 18.77% | 44.80% | 53.98% | 68.64% |
| Average Basic Shares Outstanding | 46.69% | 37.86% | 28.53% | 28.76% | 21.75% |
| Average Diluted Shares Outstanding | 46.69% | 37.86% | 28.53% | 28.76% | 21.75% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |